Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged \> 18 years old~* HIV-1 positive~* Eligible for antiretroviral treatment with CD4 T cell count \< 50 cells/μl~* BMI \< 18~Exclusion Criteria:~* Patients with smear-positive pulmonary TB~* Patients who fulfill the diagnostic criteria for smear-negative pulmonary or extrapulmonary TB (http://www.who.int/tb/publications/2006/tbhiv_recommendations.pdf ).~* Previous TB treatment (history of TB medication for \> 1 month~* History of using antiretroviral drugs~* Symptomatic known underlying liver disease or transaminases \> 5x upper limit of normal~* Known or suspected drug resistance to more than one first-line TB drug according to WHO criteria but excluding HIV infection (e.g. household contacts of MDRTB patients)~* Pregnant or breast-feeding~* Patients with cryptococcal meningitis (CrAG positive with neurologic symptoms)~* Patients with other severe (opportunistic) disease such as disseminated KS, malignant lymphoma, toxoplasmosis who may not be able to tolerate anti-TB medication or require other specific therapy~* Patients with danger signs (respiratory rate \> 30 per minute, heart rate \> 120bpm, temperature \> 39oC, and unable to ambulate)~* Taking other potentially life-saving medications (e.g. for other OIs, or immunosuppressants) that are incompatible with anti-TB chemotherapy or ART~* Unable to swallow TB medications~* Unable to follow-up at the clinic for regularly scheduled follow-up (e.g. too far from clinic)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empiric TB treatment (Type: EXPERIMENTAL): Empiric initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
- ART only arm (Type: ACTIVE_COMPARATOR): ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment

Based on this trial design, predict the completion outcome and termination type (if applicable).